2. MAPK/ERK Pathway Stem Cell/Wnt Metabolic Enzyme/Protease
  3. p38 MAPK MEK ERK Endogenous Metabolite
  4. C16-PAF

C16-PAF (PAF (C16)), a phospholipid mediator, is a platelet-activating factor and ligand for PAF G-protein-coupled receptor (PAFR). C16-PAF exhibits anti-apoptotic effect and inhibits caspase-dependent death by activating the PAFR. C16-PAF is a potent MAPK and MEK/ERK activator. C16-PAF induces increased vascular permeability.

For research use only. We do not sell to patients.

C16-PAF Chemical Structure

C16-PAF Chemical Structure

CAS No. : 74389-68-7

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 USD 115 In-stock
Solution
10 mM * 1 mL in DMSO USD 115 In-stock
Solid
1 mg USD 45 In-stock
5 mg USD 100 In-stock
10 mg USD 175 In-stock
25 mg USD 386 In-stock
50 mg USD 618 In-stock
100 mg USD 990 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 15 publication(s) in Google Scholar

C16-PAF Related Antibodies

Top Publications Citing Use of Products

View All p38 MAPK Isoform Specific Products:

View All Isoforms
p38 MAPK p38α p38β MAPK13 p38δ p38γ

View All MEK Isoform Specific Products:

View All Isoforms
MEK1 MEK2 MEK5 MEK

View All ERK Isoform Specific Products:

View All Isoforms
ERK ERK1 ERK2 ERK5 ERK8

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

C16-PAF (PAF (C16)), a phospholipid mediator, is a platelet-activating factor and ligand for PAF G-protein-coupled receptor (PAFR). C16-PAF exhibits anti-apoptotic effect and inhibits caspase-dependent death by activating the PAFR. C16-PAF is a potent MAPK and MEK/ERK activator. C16-PAF induces increased vascular permeability[1][2][3][4][5].

IC50 & Target[1][4][5]

Human Endogenous Metabolite

 

ERK

 

MEK

 

In Vitro

C16-PAF (PAF (C16); 0.5-1.5 μM; for 24 hours) elicits significant concentration-dependent neuronal loss in PAFR / but not PAFR+/+ cultures. C16-PAF (1 μM) elicits neuronal death in PAFR / cells infected with EGFP alone[1].
C16-PAF (1 μM; for 24 hours) activates caspase 7 but not caspase 3 in PAFR / neurons[1].
C16-PAF is synthesized by two distinct pathways; the remodeling pathway and the de novo synthesis pathway. C16-PAF acts by binding to a unique G-protein-coupled seven transmembrane receptor[2][3].
C16-PAF (1-25 μg/ml; 6, 12, 24 h) inhibits M. smegmatis and M. bovis BCG growth in a time-dependent manner[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

C16-PAF Related Antibodies

Cell Viability Assay[1]

Cell Line: Cerebellar granule neurons (CGNs) from PAFR−/− and PAFR+/+ mice
Concentration: 0.5-1.5 μM
Incubation Time: 24 hours
Result: Elicited significant concentration-dependent neuronal loss in PAFR−/− but not PAFR+/+ cultures in serum-free media.

Western Blot Analysis[1]

Cell Line: CGNs
Concentration: 1 μM
Incubation Time: 24 hours
Result: Activated caspase 7 but not caspase 3 in PAFR−/− neurons.
Molecular Weight

523.68

Formula

C26H54NO7P
CAS No.
Appearance

Solid

Color

White to off-white

SMILES

CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP(OCC[N+](C)(C)C)([O-])=O
Structure Classification
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

-20°C, stored under nitrogen

*In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)

Solvent & Solubility
In Vitro: 

DMSO : 50 mg/mL (95.48 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H2O : 33.33 mg/mL (63.65 mM; Need ultrasonic)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 1.9096 mL 9.5478 mL 19.0956 mL
5 mM 0.3819 mL 1.9096 mL 3.8191 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: 2.5 mg/mL (4.77 mM); Suspended solution; Need ultrasonic

    This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% Corn Oil

    Solubility: ≥ 2.5 mg/mL (4.77 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).
Purity & Documentation

Purity: 99.85%

SDS (252 KB)

COA (240 KB) HNMR (277 KB) CNMR (329 KB) RP-HPLC (248 KB) MS (84 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
H2O / DMSO 1 mM 1.9096 mL 9.5478 mL 19.0956 mL 47.7391 mL
5 mM 0.3819 mL 1.9096 mL 3.8191 mL 9.5478 mL
10 mM 0.1910 mL 0.9548 mL 1.9096 mL 4.7739 mL
15 mM 0.1273 mL 0.6365 mL 1.2730 mL 3.1826 mL
20 mM 0.0955 mL 0.4774 mL 0.9548 mL 2.3870 mL
25 mM 0.0764 mL 0.3819 mL 0.7638 mL 1.9096 mL
30 mM 0.0637 mL 0.3183 mL 0.6365 mL 1.5913 mL
40 mM 0.0477 mL 0.2387 mL 0.4774 mL 1.1935 mL
50 mM 0.0382 mL 0.1910 mL 0.3819 mL 0.9548 mL
60 mM 0.0318 mL 0.1591 mL 0.3183 mL 0.7957 mL
DMSO 80 mM 0.0239 mL 0.1193 mL 0.2387 mL 0.5967 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

C16-PAF Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

C16-PAF74389-68-7PAF (C16)p38 MAPKMEKERKEndogenous MetaboliteMitogen-activated protein kinase kinaseMAPKKMAP2KExtracellular signal regulated kinasesphospholipidmediatorplatelet-activatingfactorPAFPAFRapoptoticvascularpermeabilityInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
C16-PAF
Cat. No.:
HY-108635
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (252 KB) Français - FR (252 KB) Deutsch - DE (252 KB) Norwegian - NO (252 KB) Español - ES (252 KB) Swedish - SV (252 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.